CardieX Reports Significant Revenue Drop and Increased Losses for FY2025

An announcement from CardieX ( (AU:CDX) ) is now available.

CardieX Limited reported a significant decrease in revenue for the fiscal year ending June 2025, with a 67% drop compared to the previous year, primarily due to the early conclusion of the Clinichain clinical trial. Despite a 10% increase in revenue excluding Clinichain, the company faced a 95% increase in net loss, attributed to reduced revenue and increased marketing expenses for the new Pulse device. The company’s financial position showed improvement with increased current assets and reduced liabilities, supported by successful share issuances and financing activities. However, cash flow from operations was negative, reflecting the challenges in revenue generation and cost management.

More about CardieX

CardieX Limited operates in the medical technology industry, focusing on the development and commercialization of devices and solutions for cardiovascular health management. The company is known for its innovative products such as the Pulse device and has a market focus on improving patient outcomes through advanced health monitoring technologies.

Average Trading Volume: 447,789

Technical Sentiment Signal: Sell

Current Market Cap: A$16.5M

For an in-depth examination of CDX stock, go to TipRanks’ Overview page.